10-K: Fulcrum Therapeutics Reports 2023 Financial Results and Operational Progress

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, reported its 2023 financial results and operational progress, highlighting advancements in its lead programs, losmapimod for FSHD and pociredir for SCD.

Summary

• Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to treat genetically defined rare diseases.
• The company's lead product candidate, losmapimod, is in a Phase 3 clinical trial for facioscapulohumeral muscular dystrophy (FSHD), with enrollment completed in September 2023 and topline data expected in the fourth quarter of 2024.
• Fulcrum's second clinical-stage product, pociredir, is being developed for sickle cell disease (SCD).
• The FDA lifted a full clinical hold on pociredir in August 2023, and the Phase 1b trial is being re-initiated at 12 mg and 20 mg dose levels.
• The company reported a net loss of $97.3 million for 2023, compared to $109.9 million in 2022.
• As of December 31, 2023, Fulcrum had $236.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed clinical results, the clinical hold on pociredir, and the need for additional funding, balanced by the progress of losmapimod and the potential of the company's pipeline.

Positives

• Losmapimod has shown promising results in a Phase 2b trial (ReDUX4) for FSHD, demonstrating slowing of disease progression and improved function.
• The FDA has granted orphan drug designation and fast track designation to losmapimod for FSHD.
• The FDA has granted orphan drug designation and fast track designation to pociredir for SCD.
• Pociredir has demonstrated encouraging safety and tolerability in healthy volunteers and subjects with SCD.
• Preclinical studies of pociredir have shown significant increases in HbF-expressing cells and HbF protein levels in a mouse model of SCD.
• The company has a collaboration agreement with MyoKardia, which provides potential for future milestone payments and royalties.
• The license agreement with CAMP4 expands Fulcrum's pipeline into DBA.
• The company has a strong cash position, expected to fund operations into 2026.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses for the next several years.
• The company is early in its development efforts and has only two product candidates in clinical trials.
• The ReDUX4 trial did not meet its primary endpoint of change in DUX4-driven gene expression.
• The FDA placed a full clinical hold on the IND for pociredir in February 2023 due to hematological malignancies observed in toxicology studies, although the hold was lifted in August 2023.
• The company faces substantial competition from other companies developing treatments for FSHD and SCD.
• The company is dependent on third parties for manufacturing and clinical trials.

Risks

• The company will need substantial additional funding and may be unable to raise capital when needed, which could force it to delay, reduce, or eliminate product development programs or commercialization efforts.
• Clinical drug development is a lengthy and expensive process with an uncertain outcome.
• The results of preclinical studies and early clinical trials may not be predictive of future results.
• The FDA or other regulatory authorities may not consider the endpoints of the company's clinical trials to predict or provide clinically meaningful results.
• Serious adverse events or unacceptable side effects could be identified during the development of the company's product candidates.
• The company may not be successful in its efforts to use its discovery approach to build a pipeline of product candidates.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than the company.
• The company relies on CMOs to manufacture its product candidates, and any issues with these CMOs could delay development or commercialization.
• The company relies on third parties to conduct its clinical trials, and these third parties may not perform satisfactorily.
• The company's collaborations and license agreements may not be successful.
• The company may be unable to obtain, maintain, enforce, and protect patent protection for its technology and product candidates.
• The company's product candidates, if approved, may fail to achieve market acceptance or adequate reimbursement from third-party payors.
• The company may be subject to various legal and regulatory risks, including product liability lawsuits, government investigations, and changes in healthcare laws and regulations.

Future Outlook

The company expects to report topline data from the REACH Phase 3 trial of losmapimod in the fourth quarter of 2024. The company is also re-initiating the Phase 1b clinical trial of pociredir at 12 mg and 20 mg dose levels. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2026.

Management Comments

• In October 2022, we presented data through 96 weeks from the open label extension portion of ReDUX4. Data presented showed that patients in the initial treatment-arm who continued to receive losmapimod experienced maintenance of effect through 96 weeks as measured by RWS mean change from baseline.
• Additionally, patients who crossed over from placebo to losmapimod after the initial 48-week trial period showed improvement and slowing of disease progression as measured by RWS mean change from baseline.
• Losmapimod continued to demonstrate an encouraging safety profile and was generally well-tolerated.
• 97% of participants in the initial 48 week study remained in the open label extension at week 96.
• In January 2023, we announced Phase 1b data from subjects in the 6 mg dose cohort, as well as completion of enrollment in the 6 mg and 2 mg dose cohorts and commencement of enrollment in the 12 mg dose cohort.
• Phase 1b data from subjects in the 6 mg dose cohort (n=10) showed up to 9.5% absolute HbF increases from baseline.
• These data suggested no difference in response in subjects on (n=3) and off (n=7) background hydroxyurea.
• We also observed improved biomarkers of hemolysis in evaluable subjects dosed at 6 mg.

Industry Context

Fulcrum is operating in the highly competitive biopharmaceutical industry, specifically targeting rare genetic diseases. The focus on rare diseases often involves smaller patient populations and requires significant investment in research and development. The company faces competition from both large pharmaceutical companies and smaller biotech firms, many of which have greater resources.

Comparison to Industry Standards

• Fulcrum's progress in FSHD with losmapimod is notable, as there are currently no approved therapies for this indication. Roche is evaluating RO7204239, a myostatin inhibitor, in a Phase 2 study in adults with FSHD. Avidity is evaluating AOC 1020, an siRNA antibody-oligonucleotide complex, in a Phase 1/2 clinical trial in adults with FSHD. Arrowhead Pharmaceutical is evaluating ARO-DUX4, an antibody-oligonucleotide conjugate, in adults with FSHD in a Phase 1/2a trial.
• In SCD, Fulcrum's pociredir faces competition from approved therapies like hydroxyurea, voxelotor, crizanlizumab, L-glutamine, lovo-cel, and exa-cel, as well as other therapies in development. Novo Nordisk is evaluating nDec (decitabine-tetrahydrouridine) in a Phase 2 clinical trial. Novo is also evaluating etavopivat in a Phase 2/3 clinical trial. Agios Pharmaceuticals, Inc., is evaluating mitapivat in a Phase 2/3 clinical trial in subjects with SCD. Pfizer, Inc. is evaluating GBT-601 that is anticipated to initiate a Phase 3 clinical trial in 2023, inclacumab that is being evaluated in two Phase 3 clinical trials, and PF-07209326 in a Phase 1 clinical trial. Takeda Pharmaceutical Company Limited, is evaluating TAK-755 in a Phase 1 clinical trial in participants with baseline health SCD and SCD with acute VOCs. Sangamo Therapeutics Inc. is developing SAR445136 in a Phase 1/2 clinical trial. There are also several other gene editing approaches being evaluated by Intellia Therapeutics, Inc. (in collaboration with Novartis), Editas Medicine, Inc., Graphite Bio, and Beam Therapeutics.
• Fulcrum's financial metrics are typical for a clinical-stage biotech company, with significant R&D expenses and no product revenue. The company's cash runway into 2026 is a positive sign, but it will need to raise additional capital to continue its operations beyond that point.

Legal Proceedings

• On April 28, 2023, a class action complaint was filed in the United States District Court for the District of New Jersey against the Company and current and former officers (the Securities Action).
• On May 19, 2023, the Securities Action was transferred to the United States District Court for the District of Massachusetts, captioned Celano v. Fulcrum Therapeutics, Inc., et al., Case No. 1:23-cv-11125-IT.
• On July 31, 2023, the court appointed a lead plaintiff, who filed an amended complaint on September 29, 2023.
• The Securities Action alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder against all defendants and control person violations of Section 20(a) against the individuals, related to the Companys February 2023 announcement that the FDA issued a clinical hold regarding the IND application for pociredir for the potential treatment of SCD.
• The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information related to the clinical hold and seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between March 3, 2022, and March 8, 2023, as well as attorneys fees and costs.
• On November 28, 2023, all defendants filed a motion to dismiss the Securities Action, which motion is currently pending.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, risk of losses due to clinical trial failures or delays, potential for significant gains if product candidates are successful.
• Employees: Potential job losses if the company is unable to raise additional funding or if product candidates fail, potential for significant rewards if the company is successful.
• Patients: Potential for new treatments for FSHD and SCD if the company's product candidates are successful, risk of adverse events in clinical trials.
• Suppliers: Potential for increased business if the company's product candidates are successful, risk of reduced business if the company is forced to scale back operations.
• Creditors: Risk of default if the company is unable to raise additional funding or generate sufficient revenue.

Next Steps

• Report topline data from the REACH Phase 3 trial of losmapimod in the fourth quarter of 2024.
• Re-initiate the Phase 1b clinical trial of pociredir at 12 mg and 20 mg dose levels.
• Continue research and development efforts on preclinical programs in hematology and muscle diseases.
• Seek additional funding through equity offerings, debt financings, or collaborations.

Key Dates

Keywords

Facioscapulohumeral Muscular Dystrophy, FSHD, Sickle Cell Disease, SCD, Losmapimod, Pociredir, FTX-6058, Clinical Trial, Phase 3, Phase 1b, FDA, Clinical Hold, Drug Discovery, Rare Diseases, Genetically Defined Diseases, HbF Induction, p38 Inhibitor, EED Inhibitor, MyoKardia, CAMP4 Therapeutics, Biopharmaceutical, Orphan Drug, Fast Track